期刊文献+

再析我国“看病贵看病难”现象 被引量:6

Discussion on phenomenon of inaccessibility and costliness of healthcare in China
下载PDF
导出
摘要 长期以来,"看病贵,看病难"一直成为政府、业界、学者、百姓普遍关注和争论的焦点、热点话题。究其原因,表面上看似乎是医疗服务供方的原因,但事实上在我国更为重要的却是医疗服务需方(医疗保险基金支付不足)的问题。然而政府似乎对医疗服务供方采取的措施多一点,而对医疗保险需方采取的措施少一些。由于国力有限,政府不可能保证每个公民都能享有基本医疗保险。但如果不能从根本上解决医疗服务需方经费不足的问题,那么"看病贵看病难"现象会依然存在,绝不仅仅是单靠药品降价、招标采购等措施就能解决的。文章试图通过对"看病贵看病难"现象的深层分析,提出解决这一问题的一些措施与建议。 The phenomenon of inaccessibility and costliness in healthcare has been a topic issue of government,professionals and common people for a long time in China.The government took more measurements on the medical service provider field than the medical service demander field,which is actually the cause of the phenomenon of inaccessibility and costliness in healthcare such as the shortage of medical insurance funds.Due to limited national resources,the government cannot guarantee that every citizen can enjoy the basic medical insurance.And the phenomenon of inaccessibility and costliness in healthcare still exists if we cannot fundamentally resolve fund shortage of medical service demanders instead of drug price-cut and procurement through bidding,etc.
作者 顾丽萍
出处 《南京医科大学学报(社会科学版)》 2010年第2期129-132,共4页 Journal of Nanjing Medical University(Social Sciences)
关键词 看病贵 看病难 原因 措施及建议 inaccessibility in healthcare costliness in healthcare cause measure and proposal
  • 相关文献

参考文献6

  • 1国家发展和改革委员会.集中招标采购药品价格及收费管理暂行规定》[z].2004.
  • 2卫生部,财政部,农业部.关于建立新型农村合作医疗制度的意见》[z].2003.
  • 3民政部,卫生部,国家发展和改革委员会.卫生部、国家发展和改革委员会、民政部、财政部、农业部、国家食品药品监管局、国家中药局关于加快推进新型农村合作医疗试点工作的通知[z].2006.
  • 4国务院.国务院关于开展城镇居民基本医疗保险试点的指导意见[z].2007.
  • 5穆立红,王雪涛,徐波.卫生筹资政策变化对医院的影响[J].卫生经济研究,2004,21(5):25-26. 被引量:1
  • 6唐艳,徐怀伏.药品价格管制与社会福利的经济学分析[J].中国卫生经济,2008,27(7):52-54. 被引量:8

二级参考文献11

  • 1Balance R, Pogany J, Forstner H, The world's pharmaceutical industries: an international perspective on innovation, competition and policy[R]. Prepared for United Nations Industrial Development Organization, 1992.
  • 2John A Vernon. Drug research and price controls[M]. Regulation: Winter, 2002/2003, 25 (4): 22-25.
  • 3Devidas M. Pharmaceutical cost control in Canada: does it work? [J]. Health Affairs, 2001, 20 (3): 92-103.
  • 4Hassett KA, Price controls and the evolution of pharmaceutical markets[R], American Enterprise Institute Draft Paper, 2004.
  • 5Patricia M, Richard .D, Wang Y, et al. The impact of price regulation on the launch delay of new drugs evidence from twentyfive major markets in the 1990[J]. Health Economics, 2005(14): 269-292.
  • 6Vernon JA. Examining the link between price regulation and pharmaceutical R&D investment[J]. Health Economics, 2005 (14): 1-16.
  • 7DiMasi JA, Hansen RW, Grabowski HG, The price of innovation: new estimates of drug development costs[J]. Journal of Health Economics, 2003(22):151-185.
  • 8Brouwers, Charles-Andr, Martin B, et al. Adverse consequences of OECD covernment interventions in pharmaceutical markets on the U.S. economy and consumer[R]. The Boston Consulting Group Inc, 2004.
  • 9徐凌中,Ian Forbes,刘兴柱,董树山,曲江斌,王健,孟庆跃,Pieter Degeling,张凯,朱洪彪,王仲阳,邴媛媛,王兴洲,王桂林,黄思桂,刘冬梅,王义伟.医院筹资研究概述[J].中华医院管理杂志,2002,18(7):391-394. 被引量:12
  • 10王健,王桂林,于成浩,王斌,徐凌中,曲江斌,王兴洲,Ian Forbes.卫生筹资改革对医院生产率及经济活力和社会效率的影响[J].中华医院管理杂志,2002,18(7):396-398. 被引量:11

共引文献8

同被引文献51

引证文献6

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部